Humanities
Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

Dealing with the most common side effect of statins
  • Home
  • /
  • Dealing with the most common side effect of statins
  1. Home /
  2. Archives /
  3. Vol. 31 No. 1 (2023) /
  4. Review Articles

Dealing with the most common side effect of statins

Authors

  • Martyna Janczewska samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie https://orcid.org/0000-0003-1310-4776
  • Maria Kalicka 1 Military Clinical Hospital in Lublin, al. Racławickie 23, 20-049 Lublin https://orcid.org/0000-0002-7246-6737
  • Małgorzata Piekarska Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego SPZOZ w Lublinie https://orcid.org/0000-0001-5055-4923
  • Radosław Kasperski Wojewódzki Szpital Specjalistyczny im. Kardynała Stefana Wyszyńskiego SPZOZ w Lublinie https://orcid.org/0000-0002-7364-3205
  • Joanna Kobak Medical University of Lublin, Al. Racławickie 1 20-059 Lublin https://orcid.org/0000-0003-2588-2436
  • Jakub Gryta 1 Military Clinical Hospital in Lublin, al. Racławickie 23, 20-049 Lublin https://orcid.org/0000-0003-2088-6622
  • Karolina Iwan 1 Military Clinical Hospital in Lublin, al. Racławickie 23, 20-049 Lublin https://orcid.org/0000-0001-6570-4293
  • Tomasz Krysa Specialist Hospital of Stefan Cardinal Wyszyński in Lublin https://orcid.org/0000-0002-9644-1235

DOI:

https://doi.org/10.12775/JEHS.2023.31.01.001

Keywords

cardiovascular risk, dyslipidemia, LDL, intolerance

Abstract

Statins are one of the key drugs in the treatment of cardiology patients. They lower LDL cholesterol levels, thereby reducing the risk of acute cardiovascular events. Statins are among the best studied drugs, and have been proven to be effective and safe in the treatment of dyslipidemia. Data presented in studies on the prevalence of statin intolerance (SI) varies widely, according to some studies, statin tolerance is the same as placebo, however, this is a common problem in clinical practice. The most common reported symptoms of SI include muscle pain. Patients are often afraid of starting satin treatment because of possible side effects. The appearance of myopathy in patients results in their discontinuation of therapy, which results in increased cardiovascular risk. In order to minimize the risk of SI, particularly statin-associated muscular pain (SI), a key role is played by discussion with the patient, exclusion of nocebo effects, identification of risk factors, dose modification and possible discontinuation of the drug. The purpose of this paper is to review the problem of the most common of the adverse effects of statins- myopathy, in terms of incidence, probable cause, and recommended treatment of patients.

References

Attardo, S., Musumeci, O., Velardo, D., & Toscano, A. (2022). Statins Neuromuscular Adverse Effects. In International Journal of Molecular Sciences (Vol. 23, Issue 15).

Pohjola-Sintonen, S.; Julkunen, H. Muscle-related adverse effects of statins. Duodecim 2014,130, 1622–1627.

Abd, T.T.; Jacobson, T.A. Statin-induced myopathy: A review and update. Expert Opin. Drug Saf. 2011,10, 373–387

Abed, W.; Abujbara, M.; Batieha, A.; Ajlouni, K. Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & genetics. Ann. Med. Surg. 2022,74, 103304.

Alonso, R.; Cuevas, A.; Cafferata, A. Diagnosis and Management of Statin Intolerance.J. Atheroscler. Thromb.2019,26, 207–215

Laufs U, Weingärtner O, Kassner U, Schatz U. State of the Art: Therapie mit Statinen [State of the Art: Statin Therapy]. Dtsch Med Wochenschr. 2022 Jan;147(1-02):62-68.

Stürzebecher PE, Schumann F, Kassner U, Laufs U. Statinintoleranz und statinassoziierte Muskelschmerzen [Statin intolerance and statin-associated muscular pain]. Herz. 2022 Jun;47(3):204-211.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207.

Collins R, Reith C, Emberson J, et. Al.. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016 Nov 19;388(10059):2532-2561.

Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81.

Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006 Apr 17;97(8A):52C-60C.

Armitage J. The safety of statins in clinical practice. Lancet. 2007 Nov 24;370(9601):1781-90.

US Food and Drug Administration. FDA Drug Safety Communication December 2011: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. http://www.fda.gov/Drugs/ DrugSafety/ucm256581.htm (accessed 15.04.2023).

SEARCH Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomized trial. Lancet 2010; 376: 1658–69

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7–22

Prieto-Merino D, Smeeth L, Staa TP, Roberts I. Dangers of non-specific composite outcome measures in clinical trials. BMJ 2013; 347: f6782.

Downloads

  • PDF

Published

2023-05-16

How to Cite

1.
JANCZEWSKA, Martyna, KALICKA, Maria, PIEKARSKA, Małgorzata, KASPERSKI, Radosław, KOBAK, Joanna, GRYTA, Jakub, IWAN, Karolina and KRYSA, Tomasz. Dealing with the most common side effect of statins. Journal of Education, Health and Sport. Online. 16 May 2023. Vol. 31, no. 1, pp. 11-16. [Accessed 19 May 2025]. DOI 10.12775/JEHS.2023.31.01.001.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 31 No. 1 (2023)

Section

Review Articles

License

Copyright (c) 2023 Martyna Janczewska, Maria Kalicka, Małgorzata Piekarska, Radosław Kasperski, Joanna Kobak, Jakub Gryta, Karolina Iwan, Tomasz Krysa

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 625
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

cardiovascular risk, dyslipidemia, LDL, intolerance
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop